Skip to content
Politically.com Search all
Menu

S 4109 119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2026

A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Official Title as Introduced Congress.gov

Introduced Mar 17, 2026 Latest action Jun 22, 2026 Sponsor: Sen. Reed, Jack [D-RI] Health
Open official Congress.gov record
Source: Congress.govUpdated 2026-09-13 19:07:03 UTC.

Source-linked procedural record

Bill journey

9 dated records

This is a chronology, not a progress score. Politically.com does not classify stages or infer what comes next. Records sharing a date are grouped because not every source field supplies a time.

Congress.gov Recently refreshed U.S. Senate XML Recently refreshed
Introduction 1 One supplied introduction date.
Official actions 6 6 dated action records.
Committees 1 1 undated relationship.
Amendments 0 No record is cached.
Text versions 2 2 dated, 0 without a supplied date.
House roll calls 0 No exact legislation-key match in the House-vote cache.
Senate roll calls 0 No exact document-key match in the Senate-vote cache.
Related measures 1 1 undated relationship.
Linked law 0 No linked law record is cached; this does not predict outcome.
  1. Official action Congress.gov

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1093)

    IntroReferral · Senate

    Open bill record

    Official action Congress.gov

    Introduced in Senate

    IntroReferral · Library of Congress · Code 10000

    Open bill record

    Text version Congress.gov

    Introduced in Senate

    A dated text-version record is available.

    Open text record
  2. Official action Congress.gov

    Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

    Committee · Senate

    Open bill record
  3. Official action Congress.gov

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.

    Calendars · Senate

    Open bill record

    Official action Congress.gov

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

    Committee · Senate

    Open bill record

    Official action Congress.gov

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

    Committee · Library of Congress · Code 14000

    Open bill record

    Text version Congress.gov

    Reported to Senate

    A dated text-version record is available.

    Open text record
View the complete bill journey as an accessible table
Every dated cached record linked to S 4109. Same-date row order does not assert procedural sequence.
Date and timeRecordOfficial detailSource
IntroductionIntroduced Introduced in the Senate. Congress.gov
Official actionRead twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1093) No additional detail supplied.IntroReferral · Senate Congress.gov
Official actionIntroduced in Senate No additional detail supplied.IntroReferral · Library of Congress · Code 10000 Congress.gov
Text versionIntroduced in Senate A dated text-version record is available. Congress.gov
Official actionCommittee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably. No additional detail supplied.Committee · Senate Congress.gov
Official actionPlaced on Senate Legislative Calendar under General Orders. Calendar No. 443. No additional detail supplied.Calendars · Senate Congress.gov
Official actionCommittee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report. No additional detail supplied.Committee · Senate Congress.gov
Official actionCommittee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report. No additional detail supplied.Committee · Library of Congress · Code 14000 Congress.gov
Text versionReported to Senate A dated text-version record is available. Congress.gov

House roll calls join only on matching Congress, legislation type, and number. Senate roll calls join only on matching source-supplied document type and number, not question text. Committee and related-measure relationships have no date in their relationship records and therefore are counted above but never placed on the chronology.

Congressional Research Service

CRS summary

Reported to Senate Jun 22, 2026

Stem Cell Therapeutic and Research Reauthorization Act of 2026This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. The bill also expands periodic reviews of the state of stem cell science to specifically include a review of the use of high-quality cord blood units and other emergent technologies to develop new therapies for potential inclusion in the program.Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Official documents

Text versions